Iranian Journal of Psychiatry and Behavioral Sciences

Published by: Kowsar

Prevalence of Depression and Its Affecting Factors in Patients Referred to Substance Abuse Treatment Centers in Guilan Province, Iran, During Year 2013

Mohammad Hassan Novin 1 , * , Hassan Eftekhar-Ardebili 2 , Azizollah Batebi 2 , Zahra Mohtasham Amiri 3 and Nahid Bazarganian Langeroodi 4
Authors Information
1 School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
2 School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
3 Department of Community Medicine, School of Medicine, Guilan University, Rasht, Iran
4 Health Center of Guilan, Guilan University of Medical Sciences, Rasht, Iran
Article information
  • Iranian Journal of Psychiatry and Behavioral Sciences: 12 (4); e58779
  • Published Online: September 29, 2018
  • Article Type: Original Article
  • Received: July 25, 2017
  • Revised: February 14, 2018
  • Accepted: July 15, 2018
  • DOI: 10.5812/ijpbs.58779

To Cite: Novin M H, Eftekhar-Ardebili H , Batebi A , Mohtasham Amiri Z , Bazarganian Langeroodi N . Prevalence of Depression and Its Affecting Factors in Patients Referred to Substance Abuse Treatment Centers in Guilan Province, Iran, During Year 2013, Iran J Psychiatry Behav Sci. Online ahead of Print ; 12(4):e58779. doi: 10.5812/ijpbs.58779.

Copyright © 2018, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
  • 1. Nutt DJ, King LA, Phillips LD, Independent Scientific Committee on D. Drug harms in the UK: A multicriteria decision analysis. Lancet. 2010;376(9752):1558-65. doi: 10.1016/S0140-6736(10)61462-6. [PubMed: 21036393].
  • 2. Salomon JA, Vos T, Hogan DR, Gagnon M, Naghavi M, Mokdad A, et al. Common values in assessing health outcomes from disease and injury: Disability weights measurement study for the global burden of disease study 2010. Lancet. 2012;380(9859):2129-43. doi: 10.1016/S0140-6736(12)61680-8. [PubMed: 23245605].
  • 3. Rossi Menezes P, Ratto LR. Prevalence of substance misuse among individuals with severe mental illness in Sao Paulo. Soc Psychiatry Psychiatr Epidemiol. 2004;39(3):212-7. doi: 10.1007/s00127-004-0730-z. [PubMed: 14999454].
  • 4. Lai HM, Cleary M, Sitharthan T, Hunt GE. Prevalence of comorbid substance use, anxiety and mood disorders in epidemiological surveys, 1990-2014: A systematic review and meta-analysis. Drug Alcohol Depend. 2015;154:1-13. doi: 10.1016/j.drugalcdep.2015.05.031. [PubMed: 26072219].
  • 5. Tolliver BK, Anton RF. Assessment and treatment of mood disorders in the context of substance abuse. Dialogues Clin Neurosci. 2015;17(2):181-90. [PubMed: 26246792]. [PubMed Central: PMC4518701].
  • 6. Farhadi Nasab AA, Manikashani KH. [Substitution therapy with Methadone and evaluation of depression in drug users in Hamadan]. SJIMU. 2008;16(2):44-50. Persian.
  • 7. Poorolajal J, Ghaleiha A, Darvishi N, Daryaei S, Panahi S. The prevalence of psychiatric distress and associated risk factors among college students using GHQ-28 questionnaire. Iran J Public Health. 2017;46(7):957-63. [PubMed: 28845407]. [PubMed Central: PMC5563878].
  • 8. Tran BX, Nguyen LH, Nong VM, Nguyen CT, Phan HT, Latkin CA. Behavioral and quality-of-life outcomes in different service models for methadone maintenance treatment in Vietnam. Harm Reduct J. 2016;13:4. doi: 10.1186/s12954-016-0091-4. [PubMed: 26837193]. [PubMed Central: PMC4736621].
  • 9. Dolan K, Salimi S, Nassirimanesh B, Mohsenifar S, Allsop D, Mokri A. Characteristics of Iranian women seeking drug treatment. J Womens Health (Larchmt). 2011;20(11):1687-91. doi: 10.1089/jwh.2010.2694. [PubMed: 21905877].
  • 10. Abbasi A, Taziki SA, Moradi M. [The prototype of drug mis.abused of opioids in the self-introduced addicts in Gorgan (North-East of Iran)]. J Gorgan Unci Med. 2006;1:22-7. Persian.
  • 11. Parvizi Fard A, Birashk B, Atefvahid MK, Shakeri J. [Comorbidity of and substance abuse among treatment-seeking addicts and normal individuals]. IJPCP. 2001;7(1 and 2):45-55. Persian.
  • 12. Ahmadvand A, Sepehrmanesh Z, Ghoreyshi F, Assarian F, Moosavi G, Saee R, et al. Prevalence of mental disorders in general population of Kashan City. Iran J Epidemiol. 2010;6(2):16-24. Persian.
  • 13. Gharagozlou H, Behin MT. Frequency of psychiatric symptoms among 150 opium addicts in Shiraz, Iran. Int J Addict. 1979;14(8):1145-9. [PubMed: 536060].
  • 14. Hosseini S, Taghipour M, Tavakkoli M, Hamta A. Demographic features of patients in methadone maintenance treatment, referred to private Mmt clinic, Sari-Iran (2009-2010). Shiraz E Med J. 2012;13(3):128-34.
  • 15. Mortazavi SS, Shati M, Malakouti SK, Mohammad K. Psychiatric comorbidities among Iranian elderly patients on methadone maintenance treatment. Arch Iran Med. 2015;18(11):740-6. [PubMed: 26497370].
  • 16. Eslami-Shahrbabaki M, Fekrat A, Mazhari S. A Study of the prevalence of psychiatric disorders in patients with methamphetamine-induced psychosis. Addict Health. 2015;7(1-2):37-46. [PubMed: 26322209]. [PubMed Central: PMC4530192].
  • 17. Pani PP, Vacca R, Trogu E, Amato L, Davoli M. Pharmacological treatment for depression during opioid agonist treatment for opioid dependence. Cochrane Database Syst Rev. 2010;(9). CD008373. doi: 10.1002/14651858.CD008373.pub2. [PubMed: 20824876].
  • 18. Grant BF, Stinson FS, Dawson DA, Chou SP, Dufour MC, Compton W, et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: Results from the National epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry. 2004;61(8):807-16. doi: 10.1001/archpsyc.61.8.807. [PubMed: 15289279].
  • 19. Peles E, Schreiber S, Naumovsky Y, Adelson M. Depression in methadone maintenance treatment patients: Rate and risk factors. J Affect Disord. 2007;99(1-3):213-20. doi: 10.1016/j.jad.2006.09.017. [PubMed: 17055063].
  • 20. Teesson M, Slade T, Mills K. Comorbidity in Australia: Findings of the 2007 national survey of mental health and wellbeing. Aust N Z J Psychiatry. 2009;43(7):606-14. doi: 10.1080/00048670902970908. [PubMed: 19530017].
  • 21. Mason BJ, Kocsis JH, Melia D, Khuri ET, Sweeney J, Wells A, et al. Psychiatric comorbidity in methadone maintained patients. J Addict Dis. 1998;17(3):75-89. doi: 10.1300/J069v17n03_07. [PubMed: 9789161].
  • 22. Kosten TR, Rounsaville BJ, Kleber HD. Predictors of 2.5-year outcome in opioid addicts: Pretreatment source of income. Am J Drug Alcohol Abuse. 1987;13(1-2):19-32. [PubMed: 3687883].
  • 23. Todadze K, Mosia S. Dynamics of opioid substitution treatmentin different initial substance user opioid dependent patients. Georgian Med News. 2016;(254):56-61. [PubMed: 27348169].
  • 24. Shi J, Zhao LY, Epstein DH, Zhao C, Shuai Y, Yan B, et al. The effect of methadone maintenance on illicit opioid use, human immunodeficiency virus and hepatitis C virus infection, health status, employment, and criminal activity among heroin abusers during 6 months of treatment in china. J Addict Med. 2007;1(4):186-90. doi: 10.1097/ADM.0b013e318156cc19. [PubMed: 21768956].
  • 25. Momtaz A, Hatami H, Noorzadeh M, Saiah Bargard M, Saki S, Shirazi Beheshti ST. The effectiveness of methadone maintenance treatment in the reduction of anxiety and depression among drug-related prisoners. Jundishapur J Health Sci. 2014.
  • 26. Yin W, Pang L, Cao X, McGoogan JM, Liu M, Zhang C, et al. Factors associated with depression and anxiety among patients attending community-based methadone maintenance treatment in China. Addiction. 2015;110 Suppl 1:51-60. doi: 10.1111/add.12780. [PubMed: 25533864].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments